Also, another analysis conducted by De Groen and his colleagues, involving a total of 275 DLBCL patients, showed that DLBCL patients with MYD88 mutation were significantly associated with high IPI score risk groups [23]. Here, MYD88 is linked to diffuse large B-cell lymphoma.